Literature DB >> 441721

[Chemotherapy of human echinococcosis with mebendazole (Vermox): preliminary clinical results].

R Ammann, A Akovbiantz, J Eckert.   

Abstract

Two patients with inoperable multiple Echinococcus granulosus infections involving the lungs and the liver (one patient) were treated with the following daily doses of mebendazole (Vermox): 3 days 1000 mg, 3 days 1500 mg, the following 3 months 30-40 mg/kg body weight. One of the patients had been treated before with mebendazole in similar doses for 3 periods of 5-6 weeks each. The patients received the drug as 500 mg tablets divided into 3 daily doses after meals. After termination of treatment a distinct regression of lung cysts was demonstrable in both patients, with the exception of one cyst. The liver cyst in one of the patients had also decreased in size. About 8 months after therapy signs of reactivation of lung cysts were observed in one patient, and a new course of mebendazole treatment was therefore started.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 441721

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  10 in total

Review 1.  Chemotherapy for larval echinococcosis in animals and humans: report of a workshop.

Authors:  P M Schantz; H Van den Bossche; J Eckert
Journal:  Z Parasitenkd       Date:  1982

2.  Evaluation of oxfendazole, praziquantel and albendazole against cystic echinococcosis: a randomized clinical trial in naturally infected sheep.

Authors:  Cesar M Gavidia; Armando E Gonzalez; Eduardo A Barron; Berenice Ninaquispe; Monica Llamosas; Manuela R Verastegui; Colin Robinson; Robert H Gilman
Journal:  PLoS Negl Trop Dis       Date:  2010-02-23

3.  Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level.

Authors:  F Witassek; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man.

Authors:  F Witassek; B Burkhardt; J Eckert; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease.

Authors:  P A Braithwaite; M S Roberts; R J Allan; T R Watson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Human echinococcosis: follow-up of 23 patients treated with mebendazole.

Authors:  P Kern
Journal:  Infection       Date:  1983 Jan-Feb       Impact factor: 3.553

Review 7.  Echinococcus granulosus infection: clinical presentation, medical treatment and outcome.

Authors:  Peter Kern
Journal:  Langenbecks Arch Surg       Date:  2003-11-05       Impact factor: 3.445

8.  Echinococcus granulosus: the influence of mebendazole therapy on the ultrastructural morphology of the germinal layer of hydatid cysts in humans and mice.

Authors:  A Verheyen
Journal:  Z Parasitenkd       Date:  1982

9.  Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results.

Authors:  G J Münst; G Karlaganis; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

10.  Lack of effect of haemodialysis on mebendazole kinetics: studies in a patient with echinococcosis and renal failure.

Authors:  H Allgayer; J Zähringer; P Bach; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.